Evenity Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Evenity market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth in the historical period can be attributed to the increasing awareness of osteoporosis and fracture prevention, the growing demand for biologic drugs, the rising elderly population, improvements in diagnostic capabilities, and the demand for bone health products.

Future market growth can be attributed to the rising acceptance of biologics and advanced injectables, the increasing prevalence of osteoporosis, the rising occurrence of chronic kidney disease (CKD), the higher prevalence of rheumatoid arthritis, and the growing incidence of comorbidities. Major trends in the forecast period include innovations in delivery systems, the integration of digital health tools, the adoption of biosimilars, new therapies, and advancements in diagnostic technologies.

The growing prevalence of osteoporosis is expected to drive the future growth of the evenity market. Osteoporosis is a condition characterized by reduced bone density and quality, resulting in fragile bones that are more susceptible to fractures. The increasing prevalence of osteoporosis is driven by an aging population with naturally declining bone density and sedentary lifestyles that weaken bone strength. Evenity is administered as a monthly injection for up to 12 months to treat osteoporosis by boosting bone formation, reducing bone resorption, and strengthening bones to prevent fractures. For example, in October 2022, a report from the UK Parliament noted that osteoporotic fractures currently cost the NHS over $5.8 billion (£4.6 billion), a figure expected to rise to approximately $7.5 billion (£6 billion) by 2030 due to the aging population. Thus, the increasing prevalence of osteoporosis is fueling the growth of the evenity market.

The rising number of drug approvals is expected to further propel the growth of the evenity market in the coming years. Drug approvals refer to the formal assessment and authorization of pharmaceutical drugs by regulatory agencies for public use. This increase in approvals is mainly driven by advancements in biotechnology, which accelerate drug discovery, and supportive regulatory frameworks, such as fast-tracked approval processes for high-demand medications. Drug approvals contribute to the growth of Evenity by expanding the availability of innovative treatment options, improving patient access, and boosting healthcare providers' confidence. For instance, in January 2024, ALM Global Properties, LLC, a US-based media company, reported that the U.S. Food and Drug Administration approved nearly 50% more new drugs in the previous year compared to 2022. Therefore, the growing number of drug approvals is accelerating the growth of the evenity market.

The rise in healthcare expenditure is also expected to drive the growth of the evenity market. Healthcare expenditure refers to the total financial resources spent on medical services, preventive care, medications, and health-related activities aimed at improving or maintaining population health. This expenditure is increasing due to the aging population’s higher demand for healthcare and advancements in technology that raise treatment costs. Healthcare spending for Evenity helps cover medication costs, improve healthcare infrastructure, and enhance access to osteoporosis treatments, particularly for the aging population. For example, in December 2023, the Centers for Medicare & Medicaid Services, a US federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, outpacing the 3.2% growth seen in 2021. As a result, rising healthcare expenditure is contributing to the growth of the evenity market.

Major companies operating in the evenity market are Amgen Inc., UCB S.A.

North America was the largest region in the evenity market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in evenity report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the evenity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Evenity (romosozumab) is a biologic medication used to treat osteoporosis in postmenopausal women who are at high risk for fractures. It works by inhibiting sclerostin, which promotes bone growth and reduces bone loss. Administered via monthly subcutaneous injections, it is typically used for up to 12 months, after which other treatments may be recommended.

The primary indications for evenity include postmenopausal osteoporosis and osteoporosis in men. Postmenopausal osteoporosis occurs due to the decrease in estrogen levels after menopause and is treated with medications such as bisphosphonates and romosozumab. Evenity is distributed through hospital pharmacies, retail pharmacies, and online platforms, serving various end users such as hospitals, clinics, specialty centers, home care settings, and research and academic institutions.

The evenity market research report is one of a series of new reports that provides evenity market statistics, including evenity industry global market size, regional shares, competitors with an evenity market share, detailed evenity market segments, market trends and opportunities, and any further data you may need to thrive in the evenity industry. This event market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The evenity market consists of sales of products including evenity injection, evenity autoinjectors, and evenity pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.